C, Castaneda L, Gu H, Wong O, Li H, Berman R, Smith C, Albright CF, Dockens R and Arroyo S (2010) The safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of BMS-708163 in young and elderly subjects. Poster presentation at the International Conference on Alzheimer...
The safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of BMS-708163 in young and elderly Japanese subjectsdoi:10.1016/j.jalz.2010.05.1819George OnoK. KondoN. YamahiraH. YoshitsuguY. ImaiMasaki Hiraoka
metabolized by CYP2C19) and its active metabolites (e.g., H4), to assess the effects of avagacestat on the pharmacokinetics of carvedilol (metabolized by CYP2C9), and to assess the effects of diltiazem (metabolized by, and a moderate inhibitor of CYP3A4) on the pharmacokinetics of av...
The primary objective of this open-label, nonrandomized, single-sequence study was to assess the effects of BMS-708163 on the pharmacokinetics of CYP-isoform specific probes: midazolam (CYP3A4), S-warfarin (CYP2C9), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) in...